Teva Pharmaceutical Industries Ltd (TEVA) Earnings: An Early Look

Page 2 of 2

Meanwhile, Teva is looking to for future growth from biosimilars, which currently represents an untapped market. Biologic drugs have been a promising area for branded-drug makers, and Teva is a player in that field, with its Tbo-filgrastim set to launch late this year to go up against Amgen, Inc. (NASDAQ:AMGN)‘s Neupogen. But if biosimilars — essentially generic versions of biologics — work as well as generic drugs have, then Teva could pioneer a whole new profit center.

In Teva’s quarterly report, investors need to watch how the company plans to address the trend toward branded-drug makers marketing their own post-patent generic versions to retain sales. Pfizer Inc. (NYSE:PFE) did that extremely well when Lipitor went off-patent, and if others follow suit, Teva needs a better plan than just cost savings to come out the competitive winner in the space.

The article Teva Pharmaceutical Earnings: An Early Look originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2